Intrinsiqq

Labiana Health S.A. (LAB.XMAD) Quality Score

LAB.XMAD
Quality51

Growth is the primary weakness (avg 35/100). Business quality is the relative bright spot.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
90/100
13.7x

Under 20x, reasonable relative to earnings

Cash Flow Multiple
0/100
-12.8x

Negative FCF, no valuation support

Revenue Growth
70/100
9.1%

5–10% CAGR, steady but not exceptional

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
80/100
-0.8%

Roughly flat, no meaningful dilution

Margin Trend
100/100
+13.8pp

Expanded 3+pp, strong improvement

Capital Structure
0/100
€31M

Positive debt with no FCF to service it

2022
€3M
€38M
2023
€3M
€42M
2024
€7M
€35M
2025
€6M
€37M
Return on Capital
80/100
18.4%

15–20%, well above cost of capital

Customize WeightsPremiumUpgrade

Labiana Health (LAB.XMAD) quality: score, margins and returns

Labiana Health (LAB.XMAD) scores 51/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 7 metrics each scored 0 to 100, on 9.7% operating margins and 18.4% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is Labiana Health (LAB.XMAD) a high-quality business?+

Labiana Health scores 51 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a 9.7% operating margin and a 18.4% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Labiana Health's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from LAB.XMAD's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Labiana Health scores well and where it falls behind.

What is Labiana Health's return on invested capital (ROIC)?+

Labiana Health earns about 18.4% on its invested capital, which is strong. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to LAB.XMAD's margins and growth on this scorecard to judge durability.

How profitable is Labiana Health?+

Labiana Health runs an operating margin of about 9.7% and a net margin of about 3.4%. Revenue has grown at roughly 7.2% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

How the market compares: US profitability statistics

Related stocks: Drug Manufacturers - Specialty & Generic

Spot a number that looks wrong?

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.